Copeptin a marker for diagnosis and prognosis in heart attack

Not Applicable

Completed

• Conditions: Chest pain; Circulatory System

• Registration Number: ISRCTN14112941
• Lead Sponsor: Silesian Medical University

Brief Summary

2018 Results article in https://pubmed.ncbi.nlm.nih.gov/29619130/ results (added 11/12/2020) 2016 Other publications in https://doi.org/10.5114/aic.2016.63627 Study design (added 05/09/2023) 2018 Results article in https://doi.org/10.1155/2018/9136971 (added 05/09/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-08-09
• Study Completion: 2018-12-31
• Last Update Posted: 18 September 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 154

Inclusion Criteria

1. Chest pain lasting five minutes or more
2. Beginning of symptoms in last six hours before admission

Exclusion Criteria

1. ST-segment elevation myocardial infarction (STEMI)
2. End-stage renal insufficiency (defined as GFR <15 ml/min/1.73m2 and/or dialysis)
3. Anemia (defined as level of hemoglobin <10 g/dl for men; <8 g/dl for women)
4. Hyponatremia (defined as level of Na+ <125mmol/l)
5. Injury or big surgery in last four weeks
6. Cancer with predicted life duration < six months
7. Pregnancy
8. Age < 18 years
9. Lack of informed consent

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. Primary diagnostic endpoint is the final diagnosis of NSTEMI<br>2. Primary prognostic endpoint is death of cardiovascular origin

Secondary Outcome Measures

Name	Time	Method
1. Secondary diagnostic endpoint is the diagnosis of ACS (NSTEMI+UA)<br>2. Secondary prognostic endpoints is as Major Adverse Cardiac and Cerebrovascular Events (MACCE) and included death of cardiovascular origin, non-fatal AMI, UA, repeated cardiac revascularization, stroke